New insights into the biology and diagnosis of splenic marginal zone lymphomas
M Donzel, L Baseggio, J Fontaine, F Pesce… - Current …, 2021 - mdpi.com
Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been
recognized as a distinct pathological entity since the WHO 2008 classification. It classically …
recognized as a distinct pathological entity since the WHO 2008 classification. It classically …
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of
lymphoproliferative disorders characterized by slow growth kinetics and a …
lymphoproliferative disorders characterized by slow growth kinetics and a …
Role of Notch2 pathway in mature B cell malignancies
In recent decades, the Notch pathway has been characterized as a key regulatory signaling
of cell-fate decisions evolutionarily conserved in many organisms and different tissues …
of cell-fate decisions evolutionarily conserved in many organisms and different tissues …
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
N Epperla, Q Zhao, SM Chowdhury, L Shea… - Journal of Hematology & …, 2022 - Springer
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma
(MZL) with an overall response rate (ORR) of 48%. However, factors associated with …
(MZL) with an overall response rate (ORR) of 48%. However, factors associated with …
New Means and Challenges in the Targeting of BTK
V Nawaratne, AK Sondhi, O Abdel-Wahab… - Clinical Cancer Research, 2024 - AACR
Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B
lymphocytes and has been a crucial therapeutic target of several generations of kinase …
lymphocytes and has been a crucial therapeutic target of several generations of kinase …
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia
K Amaador, C Thieblemont, J Trotman… - Hematological …, 2023 - Wiley Online Library
Abstract Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are
indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete …
indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete …
Retrospective characterization of nodal marginal zone lymphoma
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has
historically been difficult to define, though is now formally recognized by the World Health …
historically been difficult to define, though is now formally recognized by the World Health …
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
M Raderer, B Kiesewetter… - Therapeutic Advances in …, 2023 - journals.sagepub.com
Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue
(MALT lymphoma) is among the more common types of lymphoma accounting for up to 8 …
(MALT lymphoma) is among the more common types of lymphoma accounting for up to 8 …
[HTML][HTML] Financial toxicity interventions in hematologic malignancies are timely and necessary
CT Su - JCO Oncology Practice, 2022 - ncbi.nlm.nih.gov
Dr Sidney Farber, the first to use chemotherapy to induce remission in patients with
leukemia, proclaimed in a 1951 lecture:“Wide variation exists… in the life history and …
leukemia, proclaimed in a 1951 lecture:“Wide variation exists… in the life history and …
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
N Epperla, Q Zhao, SM Chowdhury, L Shea… - Blood …, 2023 - ashpublications.org
Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma that comprises
7% of all non-Hodgkin lymphomas. 1-3 The optimal frontline management of MZL is not well …
7% of all non-Hodgkin lymphomas. 1-3 The optimal frontline management of MZL is not well …